Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C.

ABSTRACT:

Background & aims

High-level coffee consumption has been associated with reduced progression of pre-existing liver diseases and lower risk of hepatocellular carcinoma. However, its relationship with therapy for hepatitis C virus infection has not been evaluated.

Methods

Patients (n=885) from the lead-in phase of the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial recorded coffee intake before retreatment with peginterferon α-2a (180 μg/wk) and ribavirin (1000-1200 mg/day). We assessed patients for early virologic response (2 log10 reduction in level of hepatitis C virus RNA at week 12; n=466), and undetectable hepatitis C virus RNA at weeks 20 (n=320), 48 (end of treatment, n=284), and 72 (sustained virologic response; n=157).

Results

Median log10 dr

SUBMITTER: Freedman ND 

PROVIDER: S-EPMC3109110 | biostudies-literature | 2011 Jun

REPOSITORIES: biostudies-literature